Clinical trial · Observational
Pediatric Midline Post Fossa Tumors Prognostic Factors and Outcomes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will follow children younger than 18 years with midline posterior fossa brain tumors who undergo standard surgical resection at Assiut University Hospital. The aim is to evaluate functional outcome using the modified Rankin Scale and to explore how tumor type, extent of resection, and perioperative factors are associated with postoperative morbidity and survival. Results may help improve risk stratification and guide individualized treatment strategies for pediatric patients with these tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Midline Posterior Fossa Tumors | — | UNRESOLVED | — |
| Pediatric Tumor | Childhood Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Functional Outcome After Surgical Resection of Pediatric Midline Posterior Fossa Tumors
- timeFrame
- 6 months after surgery.
- description
- Assessment of the patient's functional status using the modified Rankin Scale (mRS) after surgical resection of a midline posterior fossa tumor in children, categorized as good outcome (mRS 1-3) or poor outcome (mRS 4-6).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * patients less than 18 years old * patient with midline posterior fossa tumors * patient is fit for surgery Exclusion Criteria: * patinent older than 18 years old * patients with non-midline posterior fossa or other brain tumors. * patient is unfit for surgery . * Incomplete Data: Missing essential study data. * Secondary Malignancy: Metastatic disease.
References
Publications (0)
Data not yet available